Get started
Author

Christine J. Gu

ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
2022 · Wolf R. Wiedemeyer, Julia Gavrilyuk, et al. · Molecular Cancer Therapeutics · 76
A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates
2015 · Yi Li, Christine Gu, et al. · Journal of Chromatography A · 70
Characterization of oil sands acids in plant tissue using Orbitrap ultra‐high resolution mass spectrometry with electrospray ionization
2011 · John V. Headley, Kerry M. Peru, et al. · Rapid Communications in Mass Spectrometry · 59
An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates
2016 · Yi Li, Christine Gu, et al. · mAbs · 45
PDF
Uncialamycin-based antibody–drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect
2021 · K. C. Nicolaou, Stephan Rigol, et al. · Proceedings of the National Academy of Sciences · 42
Design, Synthesis, and Biological Investigation of Epothilone B Analogues Featuring Lactone, Lactam, and Carbocyclic Macrocycles, Epoxide, Aziridine, and 1,1-Difluorocyclopropane and Other Fluorine Residues
2020 · K. C. Nicolaou, Yogesh G. Shelke, et al. · The Journal of Organic Chemistry · 31
Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates
2015 · Tao Chen, Dian Su, et al. · Journal of Pharmaceutical and Biomedical Analysis · 29
Evaluation of PNU-159682 antibody drug conjugates (ADCs)
2020 · Dane Holte, Joseph P. Lyssikatos, et al. · Bioorganic & Medicinal Chemistry Letters · 26
Streamlined Symmetrical Total Synthesis of Disorazole B1 and Design, Synthesis, and Biological Investigation of Disorazole Analogues
2020 · K. C. Nicolaou, Johannes Krieger, et al. · Journal of the American Chemical Society · 23
Synthesis and Biological Evaluation of Shishijimicin A-Type Linker-Drugs and Antibody–Drug Conjugates
2020 · K. C. Nicolaou, Ruofan Li, et al. · Journal of the American Chemical Society · 17
Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody–Drug Conjugates, Insights into Structure–Activity Relationships, and Tubulysin–Tubulin Binding Derived from X-ray Crystallographic Analysis
2021 · K. C. Nicolaou, Saiyong Pan, et al. · The Journal of Organic Chemistry · 13
Development of an Expedient Process for the Multi-Kilogram Synthesis of Chk1 Inhibitor GDC-0425
2015 · Andreas Stumpf, Zhigang Ken Cheng, et al. · Organic Process Research & Development · 13
Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML
2022 · Debbie C. Strachan, Christine J. Gu, et al. · Cancers · 11
PDF
Design, Synthesis, and Biological Investigation of Thailanstatin A and Spliceostatin D Analogues Containing Tetrahydropyran, Tetrahydrooxazine, and Fluorinated Structural Motifs
2021 · K. C. Nicolaou, Santhosh Reddy Rekula, et al. · The Journal of Organic Chemistry · 10
Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate
2023 · Daniel Ladror, Christine Gu, et al. · Drug Metabolism and Disposition · 8
Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
2023 · Elliot Stieglitz, Christine J. Gu, et al. · JCO Precision Oncology · 4
A Phase 2 Study with Volasertib for Ven-HMA Relapsed/Refractory Acute Myeloid Leukemia Patients Guided By a Predictive Precision Medicine Platform
2023 · Joseph Wagner, Markus D. Lacher, et al. · Blood · 2
Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes
2023 · Meagan A. Jacoby, John S. Welch, et al. · Cancer Research · 2
Elucidating the structure and cytochrome P450-mediated mechanism for novel metabolites of GDC-0575 in rats
2022 · Chenghong Zhang, Sungjoon Cho, et al. · Xenobiotica · 2
AML-117: A Phase 1b Study of Selinexor and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia
2025 · Somedeb Ball, Michael T. Byrne, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2024 · Somedeb Ball, Michael T. Byrne, et al. · Blood · 1
PDF
AML-553 Revival of the PLK1 Inhibitor Volasertib in Relapsed/Refractory Acute Myeloid Leukemia
2024 · Glenn Michelson, Scott Houston, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Revival of the PLK1 Inhibitor Volasertib in Relapsed/Refractory Acute Myeloid Leukemia
2024 · Glenn Michelson, Scott Houston, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
POSTER: AML-117 A Phase 1b Study of Selinexor and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia
2025 · Somedeb Ball, Michael T. Byrne, et al. · Clinical Lymphoma Myeloma & Leukemia
Prediction of Volasertib Sensitivity in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax Plus Azacitidine
2024 · Lokesh Patil, Christine J. Gu, et al. · Blood
Works count: 49
Citation count: 487
H-index: 12
I10-index: 14
Year
Topic
Type